BioCentury | Sep 21, 2017
Tools & Techniques

On your marks

...the first closing of a series B round in April 2017; Latterell Venture Partners and Wicklow Capital...
...EBV)-positive lymphoma Phase I complete $18.4 (A) Forward Ventures; NantKwest Inc. (NASDAQ:NK); Latterell Venture Partners, Wicklow Capital...
BioCentury | Apr 7, 2017
Finance

Combo quest

...week, NantKwest Inc. (NASDAQ:NK) took another step toward bolstering its natural killer cell therapy arsenal. Wicklow Capital...
BioCentury | Apr 7, 2017
Financial News

Viracta completes venture financing

...of an $18.4 million series B round led by new investor NantKwest Inc. New investor Wicklow Capital...
BioCentury | Apr 4, 2017
Financial News

Viracta raises $18.4M, strikes NantKwest deal

...an $18.4 million series B round led by new investor NantKwest Inc. (NASDAQ:NK). New investor Wicklow Capital...
Items per page:
1 - 4 of 4
BioCentury | Sep 21, 2017
Tools & Techniques

On your marks

...the first closing of a series B round in April 2017; Latterell Venture Partners and Wicklow Capital...
...EBV)-positive lymphoma Phase I complete $18.4 (A) Forward Ventures; NantKwest Inc. (NASDAQ:NK); Latterell Venture Partners, Wicklow Capital...
BioCentury | Apr 7, 2017
Finance

Combo quest

...week, NantKwest Inc. (NASDAQ:NK) took another step toward bolstering its natural killer cell therapy arsenal. Wicklow Capital...
BioCentury | Apr 7, 2017
Financial News

Viracta completes venture financing

...of an $18.4 million series B round led by new investor NantKwest Inc. New investor Wicklow Capital...
BioCentury | Apr 4, 2017
Financial News

Viracta raises $18.4M, strikes NantKwest deal

...an $18.4 million series B round led by new investor NantKwest Inc. (NASDAQ:NK). New investor Wicklow Capital...
Items per page:
1 - 4 of 4